Pd Prevention Vs Treatment Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Task ID: pd006 [1]
Created: 2026-03-06 [2]
Slot: 0 (Priority Tasks) [3]
Status: P1 [4]
This page provides a systematic comparison of prevention versus treatment approaches for Parkinson's Disease (PD). While current therapies primarily address symptoms, there is growing emphasis on disease-modifying strategies and prevention. This scorecard evaluates each therapeutic approach on two dimensions: Prevention Potential (ability to delay or prevent onset in at-risk individuals) and Treatment Potential (ability to slow, halt, or reverse progression in diagnosed patients). [^7]
The analysis synthesizes evidence from prevention trials, risk factor studies, and disease-modifying therapy research to provide actionable recommendations for clinicians, researchers, and patients. [5]
The following table scores each major PD therapeutic approach on both prevention and treatment potential (0-10 scale):
| Approach | Prevention Potential | Treatment Potential | Evidence Level | Key Considerations |
|---|---|---|---|---|
| Levodopa/Carbidopa/Entacapone | 2 | 10 | High | Gold standard for motor symptoms; no disease-modifying evidence |
| MAO-B Inhibitors | 3 | 9 | High | Possible neuroprotective effects; widely used early |
| Dopamine Agonists | 2 | 8 | High | Motor symptom control; no prevention data |
| COMT Inhibitors | 2 | 8 | High | Adjunctive therapy; levodopa optimization |
| Deep Brain Stimulation | 0 | 9 | High | Surgical intervention for advanced disease |
| Exercise & Lifestyle | 8 | 7 | High | Strongest prevention evidence; improves symptoms |
| GLP-1 Agonists | 5 | 6 | Moderate | Disease-modifying signals in Phase 2 |
| Gene Therapy (AAV-AADC) | 1 | 5 | Moderate | Targets motor symptoms; no prevention role |
| Cell Therapy (DANSR) | 1 | 5 | Moderate | Dopamine replacement; no prevention data |
| Alpha-Syn Immunotherapy | 6 | 7 | Moderate | Active trials in prodromal/early PD |
| Mitophagy Activators | 5 | 6 | Low | Preclinical promise; early clinical |
| Iron Chelators | 4 | 4 | Low | Targeting iron accumulation; uncertain efficacy |
| GDNF/Neurotrophic Factors | 3 | 5 | Moderate | Regenerative potential; delivery challenges |
| Microbiome Modulation | 6 | 5 | Low | Emerging field; gut-brain axis research |
| Antioxidants (CoQ10, Vitamin E) | 4 | 3 | Low | Mixed trial results; theoretical benefit |
The Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism trial was the first large-scale prevention trial in PD.
The Attenuation of Disease Progression with Azilect Given Once-daily trial sought to demonstrate disease-modifying effects.
The TVP-1012 (Rasagiline) in Early Monotherapy for Parkinson's Disease trial evaluated early rasagiline use.
The Neuroprotection with Creatine trial tested creatine as neuroprotective agent.
While primarily an Alzheimer's trial, the AHEAD 3-45 study explores anti-amyloid therapy in preclinical populations and informs prevention trial design for neurodegenerative diseases.
The PPMI study is following prodromal and early PD patients to identify biomarkers that predict progression, essential for prevention trials.
| Risk Factor | Relative Risk | Prevention Implications |
|---|---|---|
| LRRK2 G2019S | 6-8x | Penetrance variable; modifier genes may modulate |
| GBA N370S | 4-5x | Lysosomal dysfunction targetable |
| SNCA Multiplication | 2-3x | Alpha-synuclein expression modifiable |
| PARK2 (Parkin) | Recessive | Early-onset; different phenotype |
| PINK1 | Recessive | Mitophagy enhancement possible |
| APOE ε4 | 2-3x | Lipid metabolism, inflammation |
| Factor | Effect | Evidence | Prevention Potential |
|---|---|---|---|
| Pesticide Exposure | 1.5-2x risk | Strong | Occupational protection |
| Rural Living | 1.3x risk | Moderate | Water source protection |
| Head Trauma | 1.5x risk | Moderate | Safety equipment |
| Milk Consumption | 1.3x risk | Weak | Uncertain mechanism |
| Low Vitamin D | 1.4x risk | Moderate | Supplementation trials |
| Factor | Hazard Ratio | Evidence | Translation |
|---|---|---|---|
| Regular Exercise | 0.6-0.7 | Strong | Immediate implementation |
| Caffeine | 0.7 | Moderate | Dose optimization |
| Smoking | 0.6 (paradoxical) | Confounded | Not recommended |
| NSAID Use | 0.7 | Moderate | Anti-inflammatory |
| Physical Activity | 0.5 | Strong | Dose-response |
These approaches primarily address motor symptoms without clear disease-modifying effects:
Levodopa/Carbidopa - Treatment: 10/10, Prevention: 2/10
MAO-B Inhibitors (Selegiline, Rasagiline, Safinamide) - Treatment: 9/10, Prevention: 3/10
Dopamine Agonists - Treatment: 8/10, Prevention: 2/10
GLP-1 Agonists (Exenatide, Liraglutide) - Treatment: 6/10, Prevention: 5/10
Alpha-Synuclein Immunotherapies - Treatment: 7/10, Prevention: 6/10
Exercise & Physical Therapy - Treatment: 7/10, Prevention: 8/10
Dietary Interventions - Treatment: 4/10, Prevention: 5/10
Sleep Optimization - Treatment: 4/10, Prevention: 6/10
Gene Therapy - Treatment: 5/10, Prevention: 1/10
Cell Therapy - Treatment: 5/10, Prevention: 1/10
Microbiome Modulation - Treatment: 5/10, Prevention: 6/10
The study of Pd Prevention Vs Treatment Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications highlighting key advances in this mechanism:
Ahuja A, Patel P, Abdijadid S. Benztropine. 2026. ↩︎ ↩︎ ↩︎
Pham CK, Sankari A, Slowik JM. Rapid Eye Movement Sleep Behavior Disorder. 2026. ↩︎ ↩︎ ↩︎
Lui F, Tsao JW. Alzheimer Disease. 2026. ↩︎ ↩︎ ↩︎
Peng Y, Zhou L, Jin Y. 'Calcium bridges built by mitochondria-associated endoplasmic reticulum membranes: potential targets for neural repair in neurological diseases'. Neural Regen Res. 2025. ↩︎ ↩︎ ↩︎
Ascherio A, Schwar## Confidence Assessment. ↩︎
Cui X, Lu X, Du S. 'Temporal Sequence of Cognitive Function and ADLs and Mediation Effect of Apathy in Parkinson''s Disease: Cross-Lagged Analyses'. Clin Gerontol. 2026. ↩︎ ↩︎ ↩︎